GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

Inclusion Criteria:

1. Age ≥ 19 years
2. Histologically diagnosed glioblastoma patients who have been confirmed the progressionof disease after attempting standard therapy (RT/CCRT and/or adjuvant chemotherapy (TMZ))
3. Karnofsky Performance Status; KPS ≥ 60 or ECOG status 0-2
4. Life expectancy > 12 weeks
5. Adequate hematologic and end organ function

Exclusion Criteria:

1. Malignancies other than disease under study within 5 years prior to the first dose ofstudy drug
2. Subjects who have received bevacizumab or other VEGF inhibitors prior to studyparticipation
3. Body Mass Index (BMI) ≥ 30 kg/m2
4. Subjects confirmed intracranial hemorrhage with non-contrast CT or MRI
5. Clinically significant cardiovascular disease
6. History of arterial or venous thromboembolism 6 months prior to study participation
7. Uncontrolled hypertension (blood pressure ≥ 150/90 mmHg with appropriateantihypertensive therapy)
8. History of hypertensive crisis or hypertensive encephalopathy
9. Subjects receiving therapeutic anticoagulation (except low molecular weight heparin orwarfarin)
10. Pregnancy or breastfeeding.
11. Subjects with active virus infection
12. Subjects with autoimmune disease/ syndromes
13. Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 oranticipation that such a live attenuated vaccine will be required during the study
14. History of severe allergic, anaphylactic, or other hypersensitivity reactions tochimeric or humanized antibodies or fusion proteins
15. Severe infections during the screening period, including but not limited tocomplications of infection, bacteremia or severe pneumonia
16. Prior allogeneic bone marrow transplantation or prior solid organ transplantation